NAC (N-Acetylcysteine)
NAC (N-Acetylcysteine)
What it is
N-acetylcysteine, commonly known as NAC, is a derivative of the amino acid cysteine. Its defining biochemical role is as a precursor to glutathione, a tripeptide produced in virtually all cells of the body and one of the primary endogenous antioxidant systems. NAC supplies cysteine, which is typically the rate-limiting substrate for glutathione synthesis. This relationship with glutathione underlies most of the pharmacological rationale for NAC's clinical use — though it is worth stating early that increases in glutathione do not reliably translate into measurable clinical benefit, and the degree to which oral supplementation meaningfully raises intracellular glutathione in healthy people remains uncertain.
NAC itself also has direct antioxidant and anti-inflammatory properties, separate from its role in glutathione production. It contains a free thiol group that can directly scavenge certain reactive oxygen species, and at higher doses it appears to modulate inflammatory signalling, including reductions in IL-8 and malondialdehyde observed in clinical studies. It is also a mucolytic agent, capable of breaking disulfide bonds in mucus glycoproteins and thinning airway secretions, which explains its long-established use in respiratory medicine.
The compound is available in several forms: oral capsules, oral solution, intravenous formulation, and inhaled preparation. These routes are not interchangeable, and this distinction matters considerably when evaluating the evidence. Oral NAC undergoes substantial first-pass metabolism, with bioavailability estimated at around 6 to 10%. This means plasma concentrations from typical oral supplementation doses of 600 to 1800 mg per day are substantially lower than those achieved with intravenous administration. Most of the strongest clinical evidence — particularly in overdose management — derives from intravenous use at pharmacological doses and cannot be extrapolated to oral supplementation. Even within oral trials, dose-response relationships are not well characterised, and regimens used in research (for example, peri-cycle dosing in PCOS trials, or 1200 to 2400 mg per day in psychiatric studies) often differ from standard consumer practice.
The category label "detoxification" here refers specifically to NAC's role in endogenous biochemical pathways — primarily glutathione synthesis and hepatic detoxification of reactive metabolites. It does not reflect commercial detox concepts, which have no bearing on how this evidence is interpreted.
What the evidence shows
NAC has one of the most clearly stratified evidence profiles of any compound sold as a supplement: very strong evidence in one narrow clinical application, moderate and population-specific evidence in certain patient groups, and limited or inconsistent evidence in the healthy supplementation context that most buyers are targeting.
Its use as an antidote in paracetamol (acetaminophen) overdose is established beyond reasonable dispute. Administered intravenously within eight hours of a toxic ingestion, NAC is near-universally hepatoprotective. This is not supplement-level evidence; it is decades of acute care pharmacology with clear mechanistic explanation and consistent clinical outcomes. It depends entirely on pharmacological dosing, intravenous delivery, and time-critical administration. It is also entirely irrelevant to the supplement question, though it is frequently cited in marketing as evidence for NAC's broader value.
In COPD, the evidence is moderate, population-specific, and outcome-dependent. Several meta-analyses support a reduction in exacerbation frequency with long-term oral NAC, primarily at 600 mg per day, and improvements in lung function markers have been reported. However, effect sizes are modest and heterogeneity between trials is substantial; outcomes vary depending on baseline disease severity, exacerbation phenotype, and dose. This is a patient population with specific oxidative stress burden, and results should not be assumed to generalise to healthy individuals.
In women with PCOS, accumulating RCT evidence supports a role for NAC in improving ovulation and reproductive outcomes. The evidence base has grown materially in recent years, but it is heterogeneous and largely derived from small, often single-region RCTs with variable comparators. The suggestion that NAC performs broadly comparably to metformin on some endpoints comes from a subset of trials; this should not be read as established equivalence, and replication in larger multicentre trials is limited.
Evidence in mood disorders, substance use disorders, and for general antioxidant effects in healthy people is preliminary and inconsistent. Several meta-analyses exist, but most are built on small, short trials with heterogeneous populations and outcomes. Effect sizes are often modest and clinical significance remains uncertain. This evidence is suggestive but uncertain, and does not support confident claims.
Five questions
Does low status cause harm? NAC is not an essential nutrient and there is no defined deficiency state. Cysteine itself is a conditionally essential amino acid, and glutathione depletion occurs in various disease states, but this does not translate to a meaningful deficiency concept for NAC in healthy people eating adequate protein.
Does supplementation prevent disease? There is no robust evidence that NAC supplementation prevents disease in healthy populations. In COPD, there is moderate evidence it reduces exacerbation frequency, which could be interpreted as disease modification in that patient group. Evidence for cancer prevention, cardiovascular protection, or cognitive protection is mechanistically interesting but not clinically established.
Does it affect biomarkers? Yes, and this is one of the more consistent findings across the literature. Oral NAC supplementation reliably increases glutathione and total antioxidant capacity in clinical studies, and reduces malondialdehyde, a marker of lipid peroxidation. It has also been shown to reduce IL-8 levels significantly. Effects on CRP, TNF-alpha, and IL-6 are less consistent; some meta-analyses show significant effects only after sensitivity analysis, and main pooled analyses are often non-significant. Biomarker changes do not reliably predict clinical benefit in healthy people.
Does it help clinical populations? Evidence is strongest in COPD, PCOS, and paracetamol overdose. In COPD, meta-analyses support reduced exacerbations and modest improvements in FEV1 and FEV1/FVC, though effect sizes vary and trial heterogeneity is high. In PCOS, a 2025 meta-analysis of 22 studies found NAC significantly increased progesterone and endometrial thickness compared to placebo; prior meta-analyses have reported improvements in ovulation and pregnancy rates, though trial quality is variable. In psychiatric populations including OCD and substance use disorders, the evidence is suggestive but uncertain, limited by small trial sizes, short durations, and inconsistent methodology.
Does it benefit healthy individuals? This is where the evidence is thinnest relative to the marketing claims. Most trials in healthy people are conducted in the context of exercise performance, where a 2023 systematic review of 16 controlled trials in healthy men found improvements in some antioxidant markers and exercise performance, but no clear effects on inflammatory or haematological markers. The literature in this area is limited in size, duration, and methodological quality. The evidence does not support confident claims about general wellness, longevity, or prevention in healthy supplementers.
Individual variation
NAC is sold broadly but its evidence base is meaningfully population-specific. In women with PCOS, the evidence is sufficient to consider it an option worth discussing with a clinician, particularly for those seeking alternatives to metformin or combining it with ovulation-stimulating treatment. The evidence does not support its use for general female health outside of this context. Men with fertility concerns have some supporting evidence from trials showing improvements in sperm quality markers in subfertile populations, though this evidence is less developed.
In people with COPD or chronic respiratory conditions, evidence supports a modest reduction in exacerbation burden with oral NAC at 600 mg per day, though relative reductions in exacerbation frequency across trials are often below 20%. Benefit appears more consistent in people with frequent exacerbations and moderate to severe disease than in those with milder presentations. For psychiatric populations, particularly those with OCD, the emerging augmentation evidence is worth awareness but does not yet support clinical recommendation.
In healthy young adults, the case for supplementation is weak. Antioxidant capacity and glutathione levels respond to NAC, but whether this produces meaningful clinical benefit in the absence of disease or depleted glutathione status is not established. People with adequate cysteine intake from dietary protein, or who are not under significant oxidative stress, are the least likely to benefit.
Older adults experience greater oxidative stress and may have lower glutathione production capacity, which makes NAC rationally interesting in this group, but direct clinical trial evidence in healthy ageing populations is limited and cannot yet support a recommendation.
Testing and status assessment
There is no routine test for NAC status because NAC is not a nutrient with a defined reference range. Glutathione can be measured in red blood cells, and this is sometimes used in research contexts as a surrogate for antioxidant capacity, but it is not a standard clinical test and its interpretation in the context of supplementation decisions is not established.
Cysteine and homocysteine can both be measured in plasma and may be relevant in specific clinical contexts, but neither provides a direct basis for NAC supplementation decisions in otherwise healthy individuals.
Safety
Overall, short-term oral use appears well tolerated in clinical trials, but long-term safety data in healthy populations is limited and not well characterised. Within those limits, oral NAC is generally well tolerated at doses up to 1800 mg per day, with gastrointestinal symptoms — nausea, vomiting, diarrhoea — being the most commonly reported adverse effects, occurring in up to 23% of patients in some studies. These are typically mild and dose-dependent. The distinctive sulphurous odour of NAC solutions often contributes to nausea, particularly with oral liquid formulations.
Intravenous NAC, used in clinical settings, carries a higher rate of adverse reactions including anaphylactoid reactions in up to 8% of patients. These are non-IgE-mediated and involve histamine release; symptoms range from flushing and urticaria to bronchospasm and hypotension. People with asthma are at roughly three-fold higher risk of these reactions during IV administration. Oral and inhaled NAC can also provoke bronchospasm in susceptible individuals with reactive airways, and those with asthma should exercise caution with any route of administration. Long-term safety data for oral supplementation beyond the doses and durations studied in clinical trials is limited, and this uncertainty should be acknowledged.
There is one safety consideration specific to exercise contexts that warrants mention: reactive oxygen species play a role in signalling pathways that drive training adaptation, and there is preclinical and some human evidence that antioxidant supplementation, including NAC, may blunt exercise-induced adaptation when taken chronically. The clinical significance of this in typical supplementation contexts is not established, but it is a relevant consideration for athletes taking NAC primarily for recovery purposes.
NAC interacts with nitroglycerin, producing severe hypotension and headache, and this combination should be avoided. Signals from preclinical and limited clinical data suggest NAC may interfere with the efficacy of some chemotherapy agents; interactions with anticoagulants are also possible due to NAC's effect on platelet aggregation; anyone on blood-thinning therapy should discuss NAC use with their prescriber. Those with a history of peptic ulceration, bronchial asthma, or severe liver or kidney impairment should use NAC with caution.
The regulatory status of NAC has been subject to dispute. In the US, the FDA previously challenged its sale as a dietary supplement given its prior approval as a drug, but as of August 2022 confirmed enforcement discretion allowing it to be sold as a supplement in capsule form. This does not constitute formal recognition as a dietary supplement ingredient under current law, and the regulatory position remains legally unresolved. Oral solution formulations remain prescription-only. In the UK and EU, oral NAC is available as a licensed mucolytic medicine and as a supplement, though licensing and dose limits vary by country.
Pregnancy and lactation data are limited. No evidence of fetal harm has been established at doses used in paracetamol overdose treatment, and some PCOS fertility trials have used NAC in the peri-conception period without reported harm, but routine supplementation in pregnancy in the absence of a clinical indication is not supported by current evidence. Nursing mothers are advised to express and discard milk for approximately 30 hours after taking NAC if using it in the overdose context; this guidance is specific to high-dose clinical use and does not apply straightforwardly to supplement doses.
What can reasonably be concluded
NAC is a compound with a clearly stratified evidence profile that the supplement market tends to flatten into a single story. Its status as a life-saving antidote in paracetamol overdose is not in dispute, but this evidence is entirely context-specific — dependent on intravenous delivery, pharmacological dosing, and time-critical administration — and tells us little about the value of taking oral capsules for general wellness. In COPD, the evidence for exacerbation reduction is moderate, with meaningful caveats around effect size and trial heterogeneity. In PCOS, the evidence for reproductive outcomes has grown and is worth taking seriously, though it is heterogeneous and not yet confirmed in large multicentre trials. In healthy people, the antioxidant biomarker effects are real but their clinical relevance is not established, and marketing extrapolation from disease-state or overdose data to general supplementation is not supported by the trial evidence.
People drawn to NAC for its glutathione-supporting properties should be aware that dietary cysteine from protein-rich food will support glutathione synthesis in most healthy individuals without supplementation, and that a meaningful oxidative stress burden — not general interest in antioxidants — is the more plausible criterion for benefit. Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.